1. Home
  2. |Insights
  3. |Medical Supply Chains: Questions Companies are Asking and Evolving Government Actions in the Aftermath of COVID-19

Medical Supply Chains: Questions Companies are Asking and Evolving Government Actions in the Aftermath of COVID-19

Webinar | 06.24.20, 7:00 AM EDT - 8:00 AM EDT

Register

Supply chains have been upended in the wake of COVID-19. Companies have configured medical supply chains for cost, efficiency and competitive advantage. Governments are challenging these assumptions. U.S. officials have called for “re-shoring” supply chains, using new tariffs and subsidies for medical equipment, pharmaceuticals, and PPE. American, European and Asian governments are looking to use their purchasing power, new laws and regulations, and trade agreements to alter global supply relationships. This webinar will provide insights across a series of topics, including:


  • What does “resiliency” mean for supply chains in the COVID-19?;
  • Export restrictions imposed as a consequence of COVID-19;
  • Prospects for nationalizing production and procurement requirements;
  • Possible subsidies and tax incentives for “re-shoring” efforts;
  • Regulatory barriers and obstacles to reconfiguration; 
  • Trusted trading partner supply chain networks; and
  • The role of national and international institutions.

For more information, please visit these areas: Crowell Global Advisors

Contact

Insights

Webinar | 10.16.25

The Artificial Intelligence Agenda from Capitol Hill to State Capitals: Where We Are and Where We Are (Probably) Going

The landscape of AI governance and regulation is shifting. Following the release of the White House’s “America’s AI Action Plan” in July 2025 and the President’s signing of related Executive Orders, the White House has emphasized (at least rhetorically) a preference for innovation, adoption, and deregulation. But that does not tell the entire story. The Administration remains committed to exercising a heavy hand in AI, including by banning the U.S. government’s procurement of so-called “woke AI,” intervening in the development of data centers and the export of the AI technology stack, imposing an export fee for certain semiconductors to China, and assuming a stake in a U.S. semiconductor company. State legislatures are also racing to implement their own regulations, particularly around AI’s use in critical areas, such as healthcare, labor and employment, and data privacy. The many sources of regulation raise the specter of a fragmented compliance environment for businesses. This webinar will delve into the Administration’s AI strategy, going beyond the headlines to analyze:...

View All Insights